[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "317 659 0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Moraitis M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 16.75, "open": 16.74, "dayLow": 16.54, "dayHigh": 17.6763, "regularMarketPreviousClose": 16.75, "regularMarketOpen": 16.74, "regularMarketDayLow": 16.54, "regularMarketDayHigh": 17.6763, "payoutRatio": 0.0, "forwardPE": -7.1630907, "volume": 1674843, "regularMarketVolume": 1674843, "averageVolume": 1106746, "averageVolume10days": 4669910, "averageDailyVolume10Day": 4669910, "bid": 12.62, "ask": 21.17, "bidSize": 2, "askSize": 2, "marketCap": 746301632, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 27.5, "allTimeHigh": 27.5, "allTimeLow": 4.807, "fiftyDayAverage": 13.834, "twoHundredDayAverage": 11.963175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 336425632, "profitMargins": 0.0, "floatShares": 22076209, "sharesOutstanding": 44715498, "sharesShort": 4226517, "sharesShortPriorMonth": 4065622, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.1258, "heldPercentInsiders": 0.02329, "heldPercentInstitutions": 0.80791, "shortRatio": 12.21, "shortPercentOfFloat": 0.2515, "impliedSharesOutstanding": 44715498, "bookValue": 6.526, "priceToBook": 2.5574625, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -77019000, "trailingEps": -6.23, "forwardEps": -2.33, "enterpriseToEbitda": -3.899, "52WeekChange": -0.31033057, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 16.69, "targetHighPrice": 84.0, "targetLowPrice": 30.0, "targetMeanPrice": 60.28571, "targetMedianPrice": 61.0, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 224906000, "totalCashPerShare": 6.695, "ebitda": -86285000, "totalDebt": 650000, "quickRatio": 19.203, "currentRatio": 19.496, "debtToEquity": 0.296, "returnOnAssets": -0.36751, "returnOnEquity": -0.56278, "freeCashflow": -45419500, "operatingCashflow": -70813000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1759531445, "regularMarketTime": 1759521601, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekLowChange": 11.883, "fiftyTwoWeekLowChangePercent": 2.47202, "fiftyTwoWeekRange": "4.807 - 27.5", "fiftyTwoWeekHighChange": -10.809999, "fiftyTwoWeekHighChangePercent": -0.3930909, "fiftyTwoWeekChangePercent": -31.033056, "earningsTimestamp": 1754539200, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "earningsCallTimestampStart": 1754564400, "earningsCallTimestampEnd": 1754564400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.23, "epsForward": -2.33, "epsCurrentYear": -2.64451, "priceEpsCurrentYear": -6.311188, "fiftyDayAverageChange": 2.856001, "fiftyDayAverageChangePercent": 0.20644796, "twoHundredDayAverageChange": 4.7268257, "twoHundredDayAverageChangePercent": 0.39511466, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "averageAnalystRating": "1.3 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "postMarketChangePercent": -0.718998, "postMarketPrice": 16.57, "postMarketChange": -0.120001, "regularMarketChange": -0.0599995, "regularMarketDayRange": "16.54 - 17.6763", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1106746, "regularMarketChangePercent": -0.358206, "regularMarketPrice": 16.69, "longName": "MBX Biosciences, Inc.", "shortName": "MBX Biosciences, Inc.", "marketState": "CLOSED", "cryptoTradeable": false, "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]